Tuesday, January 19, 2021
Home 2020

Yearly Archives: 2020

Hepion Pharma HEPA
Biotech News

News, As Huge As It Gets, From Hepion Pharma (HEPA) $2.10.

Editor / Curator -
Hapbee, EMulate, HAPB
Telehealth

A Medical Technology That Has The Highest Potential Over Any ...

Editor / Curator -
Internet Stock Review
Stand Down.

Is The Market Overvalued? Barron’s Round Table January 2000.

Editor / Curator -
dexamethasone, Hepion
CoronaVirus

Remember President Trump Taking Dexamethasone? Hepion’s (HEPA) CRV431 demonstrated reduced lung...

Editor / Curator -
PetVivo, Biotech Stock Review
Biotech News

And Slowly But Surely..We Have Another 10-Bagger. PetVivo (PETV).

Editor / Curator -
Hapbee
Telehealth

Jim Kwik and Kevin Harrington Join Hapbee Technologies (HAPB) Board.

Editor / Curator -
HAPBEE
All News

Hapbee (HAPB): The Netflix of Feelings

Editor / Curator -
Aphex
CoronaVirus

Aphex BioCleanse Systems (SNST) Signs European Supply and Private Label Agreement...

Editor / Curator -
All News

Mitesco (MITI) Expands ‘The Good Clinic’ to Colorado.

Editor / Curator -
Hapbee, Biotech Stock Review
Telehealth

Scott Donnell Used His Intuition to Launch Hapbee (HAPB). Video.

Editor / Curator -
123...19Page 1 of 19

Latest article

Internet Stock Review

Is the Bitcoin Bubble More Fraud Than Frenzy?

Bitcoin Editor / Curator -
Research Affiliates Quant Warns of Bitcoin Market Manipulation (Bloomberg) (Bloomberg) -- In 2017, Alex Pickard had made so...

Make Hay While the Sun Shines. Up 6,400%.

Biotech News Editor / Curator -
Celcius (CELH) We're Up 6,400%. Alkaline Water (WTER) We're Up 12%.Dicerna (DRNA) We're Up 700%. Ready to Breakout?BioSig (BSGM) We Have...
Internet Stock Review

And it’s Official. We Have Another Double. BioSig (BSGM) up 103% in Four Months.

Biotech News Editor / Curator -
This is crazy. Wish we were 'traders' but sadly we are not. This is the most fun we've had since 1998, pre-dotcom...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: roland@institutionalanalyst.com
© Managed by Revelers.IO Media Group Inc.